Risk of Death From Other Diseases in Lung Cancer Patients After Sublobar Resection Versus Lobectomy

• Published in: Journal of surgical oncology 2024-10
• Main Authors: Nakao, Masayuki, Suzuki, Ayumi, Ichinose, Junji, Matsuura, Yosuke, Okumura, Sakae, Mun, Mingyon
• Format: Article
• Language: English
• ISSN: 0022-4790; 1096-9098; 1096-9098
• DOI: 10.1002/jso.27927

A recent Japanese phase three clinical trial for lung cancer suggested a possible advantage of segmentectomy over lobectomy in terms of death from other diseases. This study aimed to compare the risk of death from other diseases based on surgical procedures in lung cancer patients without recurrence. We retrospectively reviewed 2121 patients without disease recurrence after curative resection for lung cancer at our institution. Patient characteristics and overall survival were compared between sublobar resection and lobectomy. The sublobar group (n = 595) had a significantly higher proportion of women, non-smokers, patients without comorbidities, patients with a history of other cancers, and patients with earlier-staged disease when compared with the lobectomy group (n = 1526). The overall survival was significantly longer in the sublobar group than in the lobectomy group (p = 0.0034). After adjusting for background characteristics in an analysis of 488 patients, the overall survival had a trend to be longer in the sublobar group than in the lobectomy group (p = 0.071). Our results suggested that the risk of death from other diseases was potentially higher after lobectomy than after sublobar resection. Although several clinical factors could influence the results, these results may support the benefit of sublobar resection, assuming that the curability of both procedures is similar.